These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

536 related items for PubMed ID: 31523999

  • 1. Elafibranor: a potential drug for the treatment of nonalcoholic steatohepatitis (NASH).
    Westerouen Van Meeteren MJ, Drenth JPH, Tjwa ETTL.
    Expert Opin Investig Drugs; 2020 Feb; 29(2):117-123. PubMed ID: 31523999
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. GFT505 for the treatment of nonalcoholic steatohepatitis and type 2 diabetes.
    Cariou B, Staels B.
    Expert Opin Investig Drugs; 2014 Oct; 23(10):1441-8. PubMed ID: 25164277
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Elafibranor improves diet-induced nonalcoholic steatohepatitis associated with heart failure with preserved ejection fraction in Golden Syrian hamsters.
    Briand F, Maupoint J, Brousseau E, Breyner N, Bouchet M, Costard C, Leste-Lasserre T, Petitjean M, Chen L, Chabrat A, Richard V, Burcelin R, Dubroca C, Sulpice T.
    Metabolism; 2021 Apr; 117():154707. PubMed ID: 33444606
    [Abstract] [Full Text] [Related]

  • 8. Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis.
    Tølbøl KS, Kristiansen MN, Hansen HH, Veidal SS, Rigbolt KT, Gillum MP, Jelsing J, Vrang N, Feigh M.
    World J Gastroenterol; 2018 Jan 14; 24(2):179-194. PubMed ID: 29375204
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Elafibranor restricts lipogenic and inflammatory responses in a human skin stem cell-derived model of NASH.
    Boeckmans J, Buyl K, Natale A, Vandenbempt V, Branson S, De Boe V, Rogiers V, De Kock J, Rodrigues RM, Vanhaecke T.
    Pharmacol Res; 2019 Jun 14; 144():377-389. PubMed ID: 31028903
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Elafibranor Inhibits Chronic Kidney Disease Progression in NASH Mice.
    Tsai HC, Chang FP, Li TH, Liu CW, Huang CC, Huang SF, Yang YY, Lee KC, Hsieh YC, Wang YW, Lee TY, Huang YH, Hou MC, Lin HC.
    Biomed Res Int; 2019 Jun 14; 2019():6740616. PubMed ID: 31321239
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. A 3-week nonalcoholic steatohepatitis mouse model shows elafibranor benefits on hepatic inflammation and cell death.
    Briand F, Heymes C, Bonada L, Angles T, Charpentier J, Branchereau M, Brousseau E, Quinsat M, Fazilleau N, Burcelin R, Sulpice T.
    Clin Transl Sci; 2020 May 14; 13(3):529-538. PubMed ID: 31981449
    [Abstract] [Full Text] [Related]

  • 17. Efficacy of elafibranor in patients with liver abnormalities especially non-alcoholic steatohepatitis: a systematic review and meta-analysis.
    Malik A, Nadeem M, Malik MI.
    Clin J Gastroenterol; 2021 Dec 14; 14(6):1579-1586. PubMed ID: 34370218
    [Abstract] [Full Text] [Related]

  • 18. Beneficial effects of elafibranor on NASH in E3L.CETP mice and differences between mice and men.
    van den Hoek AM, Verschuren L, Caspers MPM, Worms N, Menke AL, Princen HMG.
    Sci Rep; 2021 Mar 03; 11(1):5050. PubMed ID: 33658534
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.